Fat loss
Mazdutide
Dual GLP-1/glucagon agonist in Phase 3 trials showing 15-20% weight loss with metabolic benefits beyond weight reduction.
- Full name
- LY3305677 (dual glucagon and GLP-1 receptor agonist)
- Also known as
- LY3305677, GCG/GLP-1 dual agonist
- Regulatory status
- Investigational (Phase 3) | Positive Phase 2 data
Origin
Developed by Eli Lilly and Innovent Biologics as a once-weekly subcutaneous GLP-1/glucagon dual agonist. Moved from Phase 1 through Phase 2 US trials to Phase 3 in Chinese populations, with 15-20% weight loss.
Mechanism
Near-equipotent agonist at GLP-1 and glucagon receptors (GCGR). GLP-1R activation suppresses appetite; GCGR activation raises hepatic and peripheral lipid oxidation and energy expenditure. The glucagon component may preferentially mobilize visceral and hepatic fat.
Research summary
Evidence
Phase 2 US trial: 10-16 mg produced 15.6-18.1% weight loss at week 32 vs -0.9% for placebo. Phase 3 China data show up to 20.1% weight loss. GI adverse events are dose-limiting, worst at 16 mg (20% discontinuation). Cardiovascular safety is still being evaluated in ongoing outcomes trials.
Evidence tier: Investigational (Phase 3) — see the methodology note for how this is assessed.
Citations
Reported benefits
- weight loss (15-20% body weight reduction)
- reduced waist circumference
- improved glycemic control
- preferential visceral/hepatic fat loss
- potential kidney protection
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Subcutaneous injection | Once-weekly: dose escalation from 3 mg to maintenance of 10 mg or 16 mg depending on tolerability. |
Side effects
- nausea
- vomiting
- diarrhea
- constipation
- abdominal pain
- increased heart rate
- fatigue
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Access for self-experimenters is limited since it's still a Phase 3 drug. Trial participants report more weight loss and stronger appetite suppression than semaglutide alone.
Related peptides
Mixing compatibility
Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.